Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
Level 5 - mechanism / opinion, no new human data
Narrative commentary and regulatory overview without empirical data collection
PubMed 32713748 · doi:10.1016/j.japh.2020.06.024
What was done
This is an informational commentary outlining the regulatory distinctions between traditional compounding pharmacies (503A) and outsourcing compounding facilities (503B) established after the 2012 fungal meningitis outbreak. It describes FDA policies regarding bulk drug substance use by 503B facilities and discusses practitioner participation in the nomination process for the FDA 503B Bulk Drug Substance list.
What was found
The abstract provides no empirical findings or numerical data. It notes that 503B facilities are legally restricted from compounding with bulk drug substances unless the substance appears on the FDA drug shortage list or the designated 503B Bulk Drug Substance list.
Why it matters
It clarifies regulatory boundaries governing compounding facilities in the United States and highlights mechanisms for clinicians and pharmacists to provide input on bulk drug nominations.
Limits
This is a descriptive regulatory commentary containing no primary empirical data, clinical outcomes, or systematic evaluation of safety or policy effectiveness.
Cited by
- supports Under FDA compounding rules, compounded medications can be prepared either during an official shortage or to meet a unique clinical need of an individual patient.